The World Health Organization has recommended clinical trials for the Ervebo vaccine in the Democratic Republic of the Congo to combat an ongoing outbreak, according to Al Jazeera. The current health emergency involves infections caused by the Bundibugyo virus, according to the U.S. Centers for Disease Control and Prevention.
WHO Vaccine Recommendations and Clinical Trials
Public health authorities are accelerating vaccine trials as the death toll in the Democratic Republic of the Congo surpasses 1,700 fatalities, according to Al Jazeera. The World Health Organization recommended deploying clinical trials for the Ervebo vaccine to evaluate its efficacy against the active viral strains. Concurrently, the Africa CDC plans to roll out the Zaire vaccine in the region, according to the Agence de Presse Africaine.
The outbreak stems from the Bundibugyo virus, a specific strain of orthoebolavirus found primarily in sub-Saharan Africa, according to the U.S. Centers for Disease Control and Prevention.
Public Health Risk and International Monitoring
Despite the high fatality count in Central Africa, federal health officials emphasize that the overall risk to the American public and international travelers remains low, according to the U.S. Centers for Disease Control and Prevention. No cases of the disease from this specific outbreak have been confirmed inside the United States.
The U.S. Centers for Disease Control and Prevention has maintained active guidance for healthcare providers and public health departments regarding entry screening and monitoring protocols for individuals arriving from affected areas. Travelers returning from regions experiencing active transmission are subjected to standard 21-day health monitoring periods to prevent imported cases.
Keep reading